The pharmaceutical lobby is mounting a last-ditch effort to add a measure to an opioid abuse bill that would block an increase to the portion of a drug’s cost the industry must cover under Medicare, sources tell the Washington Examiner.

The Pharmaceutical Research and Manufacturers of America is under pressure to fix the so-called “doughnut hole” after the influential industry group failed to add a measure addressing the issue to a prior bill to fund the Department of Health and Human Services.

Recommended Stories

Medicare could have saved nearly $1 billion by using generics, study finds

Merck sues over drug price negotiations in Democratic Inflation Reduction Act

Medicare pays more for drugs than other programs